Gilead subsidiary Kite Pharma to open CAR-T manufacturing facility in Maryland

pharmafile | April 29, 2019 | News story | Manufacturing and Production, Sales and Marketing CAR-T, Gilead, Manufacturing Facility, Maryland, kite pharma 

Gilead Sciences subsidiary Kite Pharma has announced plans to open a new CAR-T manufacturing facility in Frederick County, Maryland (US).

The new 20-acre site will extend the firm’s ability to manufacture various CAR-T therapies including Kite’s cancer treatment Yescarta.

Tim Moore, Executive VP of Technical Operations at Kite, explained: “This new facility in Frederick County builds on our substantial technical capabilities and rapid progress in making personalised CAR-T and TCR cell therapies for people with cancer.”

“As we advance our industry-leading cell therapy pipeline and seek to help a growing number of people with cancer, expanding and investing in our manufacturing capabilities is essential.”

The complex, multi-stage, manufacturing process involves genetically engineering patient’s own T-cells in order to ensure that they recognise and destroy cancer cells.

The Fredrick County site will act as part of a network of CAR-T manufacturing facilities which includes sites in California and the Netherlands.

“With the Frederick County site, we will have the opportunity to build and design the facility tailored to our own innovative processes and with state-of-the-art features that will enable us to meet the future needs for cell therapies,” Moore added.

Louis Goss

Related Content

Touchlight completes expansion of one of world’s largest DNA manufacturing facilities in London

Touchlight, a company that focuses on pioneering enzymatic DNA production, has announced that it has …

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech …


‘It’s Time for Trodelvy’: Charity launches petition against Gilead for drug access

The charity Breast Cancer Now has launched a petition calling on Gilead to provide free-of-charge …

Latest content